OPTHEA LIMITED - Announcements

0.00%

60.0¢

Market Cap $820.7M

Healthcare Biotechnology

Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The... Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The Company has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).More

MEMPHASYS LIMITED

Many are concerned about global falling birthrates. This diverse stock has solutions. Here, then, one can’t afford to miss perusing what ASX-listed fertility tech healthcare smallcap Memphasys Ltd (ASX:MEM) can offer the world.

Announcements

Filter Results

All Price Sensitive Only

OPT	Opthea Completes Recruitment in Ph2a Trial of OPT-302 in DME	PRICE SENSITIVE	07/01/20	74.37KB	Share
OPT	Ceasing to be a substantial holder		16/12/19	308.89KB	Share
OPT	Becoming a substantial holder		12/12/19	912.67KB	Share
OPT	Change in substantial holding		10/12/19	1.47MB	Share
OPT	Ceasing to be a substantial holder		10/12/19	228.14KB	Share
OPT	Completion of A$50 million Institutional Placement		06/12/19	184.08KB	Share
OPT	Becoming a substantial holder		05/12/19	192.05KB	Share
OPT	Appendix 3B		02/12/19	161.8KB	Share
OPT	Opthea Equity Raising Presentation	PRICE SENSITIVE	02/12/19	9.51MB	Share
OPT	Opthea Raises A$50 million in Institutional Placement	PRICE SENSITIVE	02/12/19	80.26KB	Share
OPT	Ceasing to be a substantial holder		28/11/19	336.95KB	Share
OPT	Becoming a substantial holder		26/11/19	756.91KB	Share
OPT	Ceasing to be a substantial holder		25/11/19	181.95KB	Share
OPT	Results of Meeting		21/11/19	149.57KB	Share
OPT	Opthea CEO Presentation to the 2019 AGM		21/11/19	1.62MB	Share
OPT	Opthea Chairman Address to the 2019 AGM		21/11/19	69.72KB	Share
OPT	Change in substantial holding		20/11/19	107.72KB	Share
OPT	Ceasing to be a substantial holder		29/10/19	359.3KB	Share
OPT	Opthea Clinical Data Published in Leading Ophthalmic Journal		29/10/19	94.9KB	Share
OPT	Becoming a substantial holder		24/10/19	682.8KB	Share
OPT	Notice of Annual General Meeting and Proxy Form		18/10/19	893.61KB	Share
OPT	Appendix 4G and Corporate Governance Statement 2019		18/10/19	928.3KB	Share
OPT	Annual Report 2019		18/10/19	3.43MB	Share
OPT	Opthea Presentation for Ophthalmology Innovation Summit	PRICE SENSITIVE	11/10/19	997.17KB	Share
OPT	Opthea Presents Additional Data from Ph2b Trial at OIS in US	PRICE SENSITIVE	11/10/19	121.49KB	Share
OPT	Change in substantial holding		09/10/19	384.58KB	Share
OPT	Becoming a substantial holder		08/10/19	452.65KB	Share
OPT	Ceasing to be a substantial holder		08/10/19	102.1KB	Share
OPT	Opthea to Present at Ophthalmology Innovation Summit in US		03/10/19	106.59KB	Share
OPT	Opthea Receives A$14.6m R&D Tax Incentive	PRICE SENSITIVE	01/10/19	60.71KB	Share
OPT	Appendix 3B		30/09/19	151.77KB	Share
OPT	Change in substantial holding		13/09/19	120.44KB	Share
OPT	Opthea Presentation for EURETINA Congress	PRICE SENSITIVE	06/09/19	987.15KB	Share
OPT	Opthea Presents Positive Phase 2b Data at EURETINA Congress	PRICE SENSITIVE	06/09/19	79.58KB	Share
OPT	Opthea Ph2b of OPT-302 in wAMD to be Presented at EURETINA	PRICE SENSITIVE	04/09/19	74.15KB	Share
OPT	Change in substantial holding		29/08/19	95.55KB	Share
OPT	Change in substantial holding		27/08/19	58.55KB	Share
OPT	Change in substantial holding		19/08/19	92.19KB	Share
OPT	Change in substantial holding		15/08/19	80.62KB	Share
OPT	Becoming a substantial holder		14/08/19	167.28KB	Share
OPT	Change in substantial holding		14/08/19	330.21KB	Share
OPT	Appendix 3B		14/08/19	151.11KB	Share
OPT	Preliminary Final Report	PRICE SENSITIVE	09/08/19	566.93KB	Share
OPT	Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302	PRICE SENSITIVE	07/08/19	259.31KB	Share
OPT	Opthea to Host Investor Teleconference		05/08/19	67.26KB	Share
OPT	Trading Halt	PRICE SENSITIVE	05/08/19	285.25KB	Share
OPT	Opthea European Patent Application to be Granted	PRICE SENSITIVE	30/07/19	73.67KB	Share
OPT	Opthea Provides Timing Update on OPT-302 Clinical Trials	PRICE SENSITIVE	22/07/19	70.38KB	Share
OPT	Change in substantial holding		04/06/19	333KB	Share
OPT	Opthea Completes Final Patient Visit in Phase 2b wAMD Trial	PRICE SENSITIVE	15/05/19	112.44KB	Share
OPT	Appendix 3B		12/04/19	183.29KB	Share
OPT	Change of Director's Interest Notice - MB		05/04/19	160.26KB	Share
OPT	Change of Director's Interest Notice - MS		19/03/19	160.83KB	Share
OPT	Change of Director's Interest Notice - GK		19/03/19	161.93KB	Share
OPT	Change of Director's Interest Notice - MB		19/03/19	153.81KB	Share
OPT	Appendix 3B		19/03/19	181.82KB	Share
OPT	Opthea Added to the S&P/ASX All Ordinaries Index		18/03/19	85.44KB	Share
OPT	S&P DJI Announces March 2019 Quarterly Rebalance	PRICE SENSITIVE	08/03/19	175.31KB	Share
OPT	Opthea Ph2b Trial Advances With 2nd Positive Safety Review	PRICE SENSITIVE	07/03/19	146.14KB	Share
OPT	Opthea Half Year Report and Accounts	PRICE SENSITIVE	25/02/19	847.64KB	Share
OPT	Opthea Granted Japanese Patent Covering OPT-302	PRICE SENSITIVE	29/01/19	87.34KB	Share
OPT	Becoming a substantial holder		04/12/18	287.31KB	Share
OPT	Becoming a substantial holder		04/12/18	272.3KB	Share
OPT	Change of Director's Interest Notice - GK		30/11/18	185.9KB	Share
OPT	Change of Director's Interest Notice - MB		30/11/18	165.76KB	Share
OPT	Appendix 3B		30/11/18	179.25KB	Share
OPT	Change in substantial holding		30/11/18	181.42KB	Share
OPT	Results of Meeting		29/11/18	51.49KB	Share
OPT	Opthea CEO Presentation to the 2018 AGM		29/11/18	1.85MB	Share
OPT	Opthea Chairman Address to the 2018 AGM		29/11/18	154.28KB	Share
OPT	Appendix 3B		28/11/18	178.14KB	Share
OPT	Opthea Options Exercise Generates Proceeds of A$13.3m	PRICE SENSITIVE	28/11/18	81.17KB	Share
OPT	Opthea confirms final patient enrolment in Ph2b wAMD trial	PRICE SENSITIVE	26/11/18	72.5KB	Share
OPT	Appendix 3B		21/11/18	178.29KB	Share
OPT	Appendix 3B		16/11/18	178.32KB	Share
OPT	Change in substantial holding		15/11/18	184.93KB	Share
OPT	Opthea Phase 2b wAMD trial fully recruited ahead of schedule	PRICE SENSITIVE	14/11/18	72.23KB	Share
OPT	Appendix 3B		12/11/18	177.86KB	Share
OPT	Appendix 3B		09/11/18	177.92KB	Share
OPT	Change in substantial holding		09/11/18	187.49KB	Share
OPT	Appendix 3B		02/11/18	177.75KB	Share
OPT	Opthea Receives A$12m R&D Tax Incentive	PRICE SENSITIVE	31/10/18	71.93KB	Share
OPT	Letter to Option Holders		30/10/18	382.91KB	Share
OPT	Opthea Provides Update on Key Opinion Leader Forum		29/10/18	77.51KB	Share
OPT	Notice of Annual General Meeting and Proxy Form		29/10/18	686.84KB	Share
OPT	Notice of Annual General Meeting and Proxy Form		26/10/18	615.74KB	Share
OPT	Opthea CEO Presentation of Trial Updates at OIS@AAO 2018	PRICE SENSITIVE	26/10/18	1.14MB	Share
OPT	Opthea Reports Positive Data from Ph1b DME Study of OPT-302	PRICE SENSITIVE	26/10/18	88.33KB	Share
OPT	Opthea To Present at the Ophthalmology Innovation Summit		24/10/18	75.94KB	Share
OPT	Appendix 3B		22/10/18	177.05KB	Share
OPT	Appendix 3B		15/10/18	177.08KB	Share
OPT	Appendix 3B		28/09/18	180.83KB	Share
OPT	Change in substantial holding		26/09/18	278.79KB	Share
OPT	Opthea to Host wAMD and DME Key Opinion Leader Forum		24/09/18	74.08KB	Share
OPT	Appendix 3B		20/09/18	160.23KB	Share
OPT	Opthea Doses First Patients in Australia for Phase 2a in DME	PRICE SENSITIVE	17/09/18	74.47KB	Share
OPT	Opthea presents Ph1/2a wAMD data at Retina Society Meeting	PRICE SENSITIVE	14/09/18	150.94KB	Share
OPT	Opthea Receives Positive Safety Review for Ph2b wAMD Trial	PRICE SENSITIVE	05/09/18	72.76KB	Share
OPT	Appendix 4G and Corporate Governance Statement 2018		28/08/18	400.36KB	Share
OPT	Opthea Appendix 4E and Annual Report 2018	PRICE SENSITIVE	28/08/18	1.49MB	Share

OPT Opthea Completes Recruitment in Ph2a Trial of OPT-302 in DME
07/01/20	PRICE SENSITIVE	74.37KB	Share
OPT Ceasing to be a substantial holder
16/12/19		308.89KB	Share
OPT Becoming a substantial holder
12/12/19		912.67KB	Share
OPT Change in substantial holding
10/12/19		1.47MB	Share
OPT Ceasing to be a substantial holder
10/12/19		228.14KB	Share
OPT Completion of A$50 million Institutional Placement
06/12/19		184.08KB	Share
OPT Becoming a substantial holder
05/12/19		192.05KB	Share
OPT Appendix 3B
02/12/19		161.8KB	Share
OPT Opthea Equity Raising Presentation
02/12/19	PRICE SENSITIVE	9.51MB	Share
OPT Opthea Raises A$50 million in Institutional Placement
02/12/19	PRICE SENSITIVE	80.26KB	Share
OPT Ceasing to be a substantial holder
28/11/19		336.95KB	Share
OPT Becoming a substantial holder
26/11/19		756.91KB	Share
OPT Ceasing to be a substantial holder
25/11/19		181.95KB	Share
OPT Results of Meeting
21/11/19		149.57KB	Share
OPT Opthea CEO Presentation to the 2019 AGM
21/11/19		1.62MB	Share
OPT Opthea Chairman Address to the 2019 AGM
21/11/19		69.72KB	Share
OPT Change in substantial holding
20/11/19		107.72KB	Share
OPT Ceasing to be a substantial holder
29/10/19		359.3KB	Share
OPT Opthea Clinical Data Published in Leading Ophthalmic Journal
29/10/19		94.9KB	Share
OPT Becoming a substantial holder
24/10/19		682.8KB	Share
OPT Notice of Annual General Meeting and Proxy Form
18/10/19		893.61KB	Share
OPT Appendix 4G and Corporate Governance Statement 2019
18/10/19		928.3KB	Share
OPT Annual Report 2019
18/10/19		3.43MB	Share
OPT Opthea Presentation for Ophthalmology Innovation Summit
11/10/19	PRICE SENSITIVE	997.17KB	Share
OPT Opthea Presents Additional Data from Ph2b Trial at OIS in US
11/10/19	PRICE SENSITIVE	121.49KB	Share
OPT Change in substantial holding
09/10/19		384.58KB	Share
OPT Becoming a substantial holder
08/10/19		452.65KB	Share
OPT Ceasing to be a substantial holder
08/10/19		102.1KB	Share
OPT Opthea to Present at Ophthalmology Innovation Summit in US
03/10/19		106.59KB	Share
OPT Opthea Receives A$14.6m R&D Tax Incentive
01/10/19	PRICE SENSITIVE	60.71KB	Share
OPT Appendix 3B
30/09/19		151.77KB	Share
OPT Change in substantial holding
13/09/19		120.44KB	Share
OPT Opthea Presentation for EURETINA Congress
06/09/19	PRICE SENSITIVE	987.15KB	Share
OPT Opthea Presents Positive Phase 2b Data at EURETINA Congress
06/09/19	PRICE SENSITIVE	79.58KB	Share
OPT Opthea Ph2b of OPT-302 in wAMD to be Presented at EURETINA
04/09/19	PRICE SENSITIVE	74.15KB	Share
OPT Change in substantial holding
29/08/19		95.55KB	Share
OPT Change in substantial holding
27/08/19		58.55KB	Share
OPT Change in substantial holding
19/08/19		92.19KB	Share
OPT Change in substantial holding
15/08/19		80.62KB	Share
OPT Becoming a substantial holder
14/08/19		167.28KB	Share
OPT Change in substantial holding
14/08/19		330.21KB	Share
OPT Appendix 3B
14/08/19		151.11KB	Share
OPT Preliminary Final Report
09/08/19	PRICE SENSITIVE	566.93KB	Share
OPT Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302
07/08/19	PRICE SENSITIVE	259.31KB	Share
OPT Opthea to Host Investor Teleconference
05/08/19		67.26KB	Share
OPT Trading Halt
05/08/19	PRICE SENSITIVE	285.25KB	Share
OPT Opthea European Patent Application to be Granted
30/07/19	PRICE SENSITIVE	73.67KB	Share
OPT Opthea Provides Timing Update on OPT-302 Clinical Trials
22/07/19	PRICE SENSITIVE	70.38KB	Share
OPT Change in substantial holding
04/06/19		333KB	Share
OPT Opthea Completes Final Patient Visit in Phase 2b wAMD Trial
15/05/19	PRICE SENSITIVE	112.44KB	Share
OPT Appendix 3B
12/04/19		183.29KB	Share
OPT Change of Director's Interest Notice - MB
05/04/19		160.26KB	Share
OPT Change of Director's Interest Notice - MS
19/03/19		160.83KB	Share
OPT Change of Director's Interest Notice - GK
19/03/19		161.93KB	Share
OPT Change of Director's Interest Notice - MB
19/03/19		153.81KB	Share
OPT Appendix 3B
19/03/19		181.82KB	Share
OPT Opthea Added to the S&P/ASX All Ordinaries Index
18/03/19		85.44KB	Share
OPT S&P DJI Announces March 2019 Quarterly Rebalance
08/03/19	PRICE SENSITIVE	175.31KB	Share
OPT Opthea Ph2b Trial Advances With 2nd Positive Safety Review
07/03/19	PRICE SENSITIVE	146.14KB	Share
OPT Opthea Half Year Report and Accounts
25/02/19	PRICE SENSITIVE	847.64KB	Share
OPT Opthea Granted Japanese Patent Covering OPT-302
29/01/19	PRICE SENSITIVE	87.34KB	Share
OPT Becoming a substantial holder
04/12/18		287.31KB	Share
OPT Becoming a substantial holder
04/12/18		272.3KB	Share
OPT Change of Director's Interest Notice - GK
30/11/18		185.9KB	Share
OPT Change of Director's Interest Notice - MB
30/11/18		165.76KB	Share
OPT Appendix 3B
30/11/18		179.25KB	Share
OPT Change in substantial holding
30/11/18		181.42KB	Share
OPT Results of Meeting
29/11/18		51.49KB	Share
OPT Opthea CEO Presentation to the 2018 AGM
29/11/18		1.85MB	Share
OPT Opthea Chairman Address to the 2018 AGM
29/11/18		154.28KB	Share
OPT Appendix 3B
28/11/18		178.14KB	Share
OPT Opthea Options Exercise Generates Proceeds of A$13.3m
28/11/18	PRICE SENSITIVE	81.17KB	Share
OPT Opthea confirms final patient enrolment in Ph2b wAMD trial
26/11/18	PRICE SENSITIVE	72.5KB	Share
OPT Appendix 3B
21/11/18		178.29KB	Share
OPT Appendix 3B
16/11/18		178.32KB	Share
OPT Change in substantial holding
15/11/18		184.93KB	Share
OPT Opthea Phase 2b wAMD trial fully recruited ahead of schedule
14/11/18	PRICE SENSITIVE	72.23KB	Share
OPT Appendix 3B
12/11/18		177.86KB	Share
OPT Appendix 3B
09/11/18		177.92KB	Share
OPT Change in substantial holding
09/11/18		187.49KB	Share
OPT Appendix 3B
02/11/18		177.75KB	Share
OPT Opthea Receives A$12m R&D Tax Incentive
31/10/18	PRICE SENSITIVE	71.93KB	Share
OPT Letter to Option Holders
30/10/18		382.91KB	Share
OPT Opthea Provides Update on Key Opinion Leader Forum
29/10/18		77.51KB	Share
OPT Notice of Annual General Meeting and Proxy Form
29/10/18		686.84KB	Share
OPT Notice of Annual General Meeting and Proxy Form
26/10/18		615.74KB	Share
OPT Opthea CEO Presentation of Trial Updates at OIS@AAO 2018
26/10/18	PRICE SENSITIVE	1.14MB	Share
OPT Opthea Reports Positive Data from Ph1b DME Study of OPT-302
26/10/18	PRICE SENSITIVE	88.33KB	Share
OPT Opthea To Present at the Ophthalmology Innovation Summit
24/10/18		75.94KB	Share
OPT Appendix 3B
22/10/18		177.05KB	Share
OPT Appendix 3B
15/10/18		177.08KB	Share
OPT Appendix 3B
28/09/18		180.83KB	Share
OPT Change in substantial holding
26/09/18		278.79KB	Share
OPT Opthea to Host wAMD and DME Key Opinion Leader Forum
24/09/18		74.08KB	Share
OPT Appendix 3B
20/09/18		160.23KB	Share
OPT Opthea Doses First Patients in Australia for Phase 2a in DME
17/09/18	PRICE SENSITIVE	74.47KB	Share
OPT Opthea presents Ph1/2a wAMD data at Retina Society Meeting
14/09/18	PRICE SENSITIVE	150.94KB	Share
OPT Opthea Receives Positive Safety Review for Ph2b wAMD Trial
05/09/18	PRICE SENSITIVE	72.76KB	Share
OPT Appendix 4G and Corporate Governance Statement 2018
28/08/18		400.36KB	Share
OPT Opthea Appendix 4E and Annual Report 2018
28/08/18	PRICE SENSITIVE	1.49MB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 60.0¢		Change 0.000(0.00%)		Mkt cap ! $820.7M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

OPT (ASX) Chart

Day chart unavailable

OPTHEA LIMITED - Announcements

Announcements

Top Stories